Ke Liu, MD, PhD
Associate Director for Cell and Gene Therapy, Oncology Center of Excellence; Chief of Oncology, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
Ke Liu, MD, PhD, is Senior Vice President, Head of Regulatory Affairs & Strategy at Sana Biotechnology.
Ke has more than 20 years of experience and expertise in oncology, cell and gene therapy, including basic, translational, clinical research, drug development, and regulation.
Before joining Sana in December 2020, Dr. Liu spent more than 17 years working at the U.S. Food and Drug Administration (FDA), including the Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), and Oncology Center of Excellence (OCE), most recently serving as OCE Associate Director for Cell and Gene Therapy, and Chief of Oncology Branch in CBER’s Office of Tissues and Advanced Therapies. He oversaw the clinical evaluation and approval of many innovative cancer therapeutics with curative potential [e.g., chimeric antigen receptor (CAR) T cells, T-cell receptor (TCR)-modified T cells, genome-edited products, neoantigen-based therapies, adoptive T cell therapies, oncolytic viral therapy, dendritic cell therapy, and combinations of these immune-oncologic therapeutics with checkpoint inhibitors and other agents]. He had received many awards, such as FDA honor award for FDA Guidances writing and reviews for new drug / biologic applications as well as mentoring award.
Prior to FDA, Ke served as an associate investigator for multiple clinical trials studying a variety of new cancer therapeutics at the U.S. National Cancer Institute (NCI). He served as protocol chairperson responsible for developing and conducting a clinical trial using genetically modified cells for the treatment of cancer patients.
Ke has many publications and book chapters elaborating on scientific and regulatory perspectives on drug development, approval pathways and standards, trial endpoints and design. He is a co-inventor of a U.S. patent for cancer cell therapy.
Ke is a medical oncologist and internist, certified by the American Board of Internal Medicine (ABIM). He is a physician licensed to practice medicine in Maryland and served as a volunteer attending medical oncologist for more than 15 years at the Veterans Administration Medical Center in Washington, D.C.
Ke completed his Internal Medicine internship and residency in Albert Einstein College of Medicine, his Medical Oncology fellowship at the NCI, and additional cancer immunotherapy training at the NCI’s Surgery Branch. He obtained his MD from Henan Medical University in China and his PhD in Molecular Biology from Cornell University Graduate School of Medical Sciences.